US FDA slaps hold on PharmAthene anthrax program; shares choked
This article was originally published in Scrip
Executive Summary
Investors wasted no time in fleeing from PharmAthene on 10 August, panicked over the company's revelation the US FDA has placed a clinical hold on the firm's development program for its recombinant protective antigen (rPA) anthrax vaccine SparVax – with shares tumbling as low as 22.6%.